Effects of esomeprazole on healing of nonsteroidal anti-inflammatory drug ( NSAID)-induced gastric ulcers in the presence of a continued NSAID treatment: Characterization ... Indomethacin administration was continued, alone or combined with equivalent acid inhibitory doses of esomeprazole (5μmol/kg/day), lansoprazole ...
Peghini P.L., Katz P.O., Bracy N.A., Castell D.O. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors // Am. J. Gastroenterol. — 1998.— N 93.—. P. 763—767. 31. Richter J.E., Kahrilas P.J., Johanson J. et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD ...
All children were treated with PPI (esomeprazole) and/or prokinetic ( domperidone) in dosages according their age. 79 of 87 patients observed in catamnesis more than 1 year. Treatment was retrospectively evaluated. Most children with GERD (70,6%) got relief after PPI dose 20 mg/day, and therapy duration was less than 8 ...
Современная ревматология. 2013;7(1):82-93. DOI:10.14412/1996-7012-2013- 2374. For citation: Karateev A.E., Alekseeva L.I., Anikin S.G. A combination of naproxen and esomeprazole: Analgesic therapy on balancing cardiovascular and gastrointestinal risks. Modern Rheumatology Journal. 2013;7(1):82-93. (In Russ.) ...
Andersson Т., Rohss K., Hassan-Alin M. Pharmacokinetics (PK) and dose- response relationship of esomeprazole (E) // Gastroenterology. – 2000. – № 118. – Р. A1210. 3. Castell D., Kahrilas P. et al. Esomeprazole provides more effective healing than lansoprazole in GERD patients with erosive oesophagitis // Gut. – 2001.
6 апр 2017 ... Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night- time GERD symptoms. Aliment Pharmacol Ther, 2007, 25: 197–205. 19.
Пантопразол - эффективное и безопасным средством лечения кислотозависимых заболеваний. Длительный и выраженный антисекреторный эффект, бустро уменбшает клинические симптомы, позволяет избежать ночного кислотного прорыва или резкого повышения продукции сол.
Ингиби́торы прото́нного насо́са (синонимы: Ингиби́торы прото́нной по́мпы, Ингиби́торы прото́нового насо́са, Ингиби́торы прото́новой по́мпы, Блокаторы прото́нной по́мпы; часто употребляется аббревиатура ИПП, реже — ИПН) — лекарственные препараты, предназначенные для лечения ...
3. Andersson Т., Rohss K., Hassan-Alin M., Bredberg E. Pharmacokinetics and dose-response relationship of esomeprasole // Gastroenterology. — 2000. — 118 . — A1210. 4. Castell D., Castell D., Kahrilas P. et al. Esomeprazole provides more effective healing than lansoprazole in GERD patients with erosive oesophagitis ...
Night acid breach (NAB) found in gastroesophago reflux disease (GERD) in up to 60-80% in peptic ulcer disease of stomach and duodenum, in ... Doses varying frequency of PPI intake do not result in NAB elimination. ..... B. Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough //.
Prevention of peptic ulcers with esomeprazole in patients at risk of 40 mg or 20 mg compared with placebo reduces the incidence of peptic ulcers over 26 weeks of treatment in patients taking low-dose acetylsalicylic acid (ASA) and who are at risk for ulcer development.
Effects of esomeprazole on healing of nonsteroidal anti-inflammatory drug ( NSAID)-induced gastric ulcers in the presence of a continued NSAID
For the Spanish setting, the high-dose IV esomeprazole strategy was dominant (more effective and less costly than the no-IV esomeprazole strategy) [year 2008 values].
Esomeprazole was generally well tolerated. Conclusions Acid-suppressive treatment with once-daily esomeprazole 40 mg or 20 mg reduces the occurrence of peptic ulcers in patients at risk for ulcer development who are taking low-dose ASA.
sAll patients with peptic ulcer bleeding should be treated with 40 -mg oral esomeprazole for a total of 30 days or more depending on.
Three-day high dose esomeprazole infusion can prevent peptic ulcer rebleeding after endoscopic therapy. However, the optimal dose of oral esomeprazole is uncertain, especially for high risky patients.
Objective: The objective of the present study is to formulate a dual therapy of peptic ulcer containing antimicrobial agent amoxicillin and anti-secretory agent esomeprazole, utilizing the concept of bilayer tablet system for the effective treatment of H. pylori associated gastric/duodenal ulcer...
Esomeprazole Versus Pantoprazole to Prevent Peptic Ulcer Rebleeding.
Efficacy of a continuous high-dose intravenous infusion of esomeprazole, followed by an oral regimen after successful endoscopic therapy for peptic ulcer bleeding (PUB) was established in the PUB study (ClinicalTrials. gov identifier: NCT00251979).
On a molar basis, esomeprazole is more potent than omeprazole and the recommended dose in adults is 20 mg once daily, with twice daily doses for more severe cases of gastrointestinal reflux and peptic ulcer disease, and doses of up to 60 mg daily for Zollinger-Ellison syndrome.